# OnCo record gog-0218-icon7 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/gog-0218-icon7/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "gog-0218-icon7", "NCT00262847" ;
  schema:name "GOG-0218 & ICON7 (bevacizumab)"@en ;
  schema:description "Adding the blood-vessel blocker bevacizumab to first-line chemotherapy delayed relapse by a few months but did not extend life overall."@en ;
  schema:url <https://onco.cc/trials/gog-0218-icon7/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00262847>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1104390> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  schema:startDate "2005-09" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/mrc-ctu/>, <https://onco.cc/companies/arcagy-gineco/>, <https://onco.cc/companies/gog-foundation/> ;
  onco:people <https://onco.cc/people/jonathan-ledermann/> .